Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 8;13:987568. doi: 10.3389/fimmu.2022.987568

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wang, Zou, Li, Jiao, Wang, Zhuo, Gao, Gong, Li, Zhang, Wang, Peng, Qi, Wang, Li, Li, Shen, Zhang and Lu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Baseline serum cytokine levels related to clinical outcomes. (A) Bar Chart showing the response rate in patients with (n = 24) and without irAEs (n = 27). (B) Kaplan-Meier survival curve of PFS and OS in the irAE (n = 24) and non-irAE (n = 27) groups. (C) Kaplan-Meier survival curve of progression-free survival (PFS) and overall survival (OS) following anti-PD-L1 (n = 18) and anti-PD-1 (n = 33) treatment in irAE and non-irAE groups. (D) OS of gastrointestinal cancer patients based on BTLA and PD-1 levels. CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, PFS: progression-free survival, OS: overall survival. Kaplan-Meier survival curves were plotted for patients using the median cutoff. Statistical significance was determined using the log‐rank (Mantel-Cox) regression analysis, with the level of significance at P ≤ 0.05.